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Udenafil (Zydena, Dong-A Phamaceutical, Seoul, Korea) 
is a drug used in urology to treat erectile dysfunction and 
belongs to a class of drugs called phosphodiesterase type 5 
(PDE 5) inhibitors. Other erectile dysfunction drugs such 
as sildenafil, tadalafil and vardenafil are also PDE5 inhibi-
tors. The authors report the first literature case of anterior 
ischemic optic neuropathy (AION) associated with udena-
fil. 
Case Report
A 54-year-old male complained of decreased visual field 
in his right eye. He also had a history of sexual dysfunc-
tion, for which he was prescribed udenafil. He took his 
first dose of 100 mg udenafil three days before his visit to 
our clinic. The next day he found that his eye was mildly 
irritated, and he had a mild headache. He discussed these 
symptoms with his urologist, and his symptoms subsided 
on their own after several hours. One day before his visit 
to our clinic, he took his second dose of udenafil. The fol-
lowing morning, approximately 12 hours later, he reported 
blurred vision and a decrease in the visual field of his right 
eye. This patient did have a 20-year history of smoking but 
no history of either hypertension or hypotension, diabetes 
mellitus, hyperlipidemia, or cardiovascular disease. Upon 
examination, his best-corrected visual acuity (BCVA) 
was 20 / 25 in the right eye and 20 / 20 in the left eye. A 
pupillary examination revealed a right-sided relative affer-
ent pupillary defect. Ocular motility was normal, and the 
biomicroscopy of the anterior segment was unremarkable. 
A dilated fundus examination of the right eye revealed 
prominent swelling of the disc with a disc rim hemorrhage 
(Fig. 1). Fundoscopy of the left eye revealed a healthy but 
crowded disc with a cup-to-disc ratio of 0.2 (Fig. 1). Fundus 
fluorescein angiography showed both an inferior choroidal 
filling delay and an inferior sector filling delay of the optic 
disc in the arteriovenous phase and diffuse leakage of the 
optic disc in the late phase (Fig. 2). Automated visual fields 
(Humphrey 30-2) revealed a generalized constriction of the 
visual field in the right eye and a normal visual field in the 
left eye (Fig. 3). Optical coherence tomography revealed 
a prominent thickening of the inferior retinal nerve fiber 
layer (Fig. 4). Laboratory testing revealed a normal blood 
count, an erythrocyte sedimentation rate of 10 and a nor-
mal CRP titer. A systemic evaluation was performed by 
a physician, and there was no evidence of cardiovascular 
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We report a case of anterior ischemic optic neuropathy associated with udenafil. A 54-year-old male presented 
with an acute onset visual field defect of the right eye after udenafil use. Examination revealed a relative affer-
ent pupillary defect and a swollen disc. Automated visual fields revealed an enlarged blind spot and a narrowed 
visual field. Fluorescein angiography revealed both an inferior choroidal filling delay and an inferior sector filling 
delay of the optic disc in the arteriovenous phase as well as diffuse leakage of the optic disc in the late phase. 
Optical coherent tomography revealed increased thickness of the retinal nerve fiber layer, especially in the area 
of the inferior disc. The patient was counseled to discontinue the use of udenafil and to monitor his blood pres-
sure regularly. The disc swelling was resolved with residual optic atrophy one month after discontinuing the use 
of udenafil. 
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Fig. 1. (A) Fundus photograph of the right eye shows prominent swelling of the disc with a disc rim hemorrhage. (B) Fundus photograph 
of the left eye shows a healthy appearing but crowded disc with a cup-to-disc ratio of 0.2. 
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Fig. 2. Fluorescein angiography shows an inferior choroidal filling delay and inferior sector filling delay of the optic disc in the arteriove-
nous phase (A) as well as diffuse leakage of the optic disc in the late phase (B).
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Fig. 3. Humphrey 30-2 visual field of the left (A) and right eyes (B) at the initial examination.237
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disease, including hypertension, hypotension, diabetes, 
and hyperlipidemia. A neurologic examination was per-
formed by a neurologist and was normal, and a magnetic 
resonance image (MRI) scan of the brain with gadolinium 
enhancement was able to demonstrate that the optic nerves 
appeared normal, and that there were no white matter le-
sions, which would have been suggestive of demyelinating 
disease.
The patient was counseled to discontinue using udenafil 
and to regularly monitor his blood pressure. The patient’s 
BCVA was improved to 20 / 20, and fundoscopy showed a 
slightly pale disc one month after he had discontinued the 
use of udenafil. 
Discussion
AION is the most common acute optic neuropathy in 
people over the age of 50 [1]. The exact pathophysiology 
of AION remains unclear and is highly controversial. It is 
generally accepted that the site of the infarction is located 
in the retrolaminar portion of the optic nerve head, which 
is supplied by the short posterior ciliary arteries (SPCA), 
as this has been demonstrated histopathologically [2]. Dop-
pler studies have also corroborated these findings by show-
ing reduced blood flow in the SPCA [3]. The location of 
the impaired blood flow has been further refined by fluo-
rescein and indocyanine green angiographic studies. These 
studies have demonstrated that delayed optic disc filling 
occurs without impairment of the choroidal circulation, 
which suggests that the vasculopathy is located in the para-
optic branches of the SPCA after their branching from the 
choroidal branches rather than in the short ciliary arteries 
[4,5]. 
Hayreh et al. [6] have suggested that nocturnal hypo-
tension may be an important precipitating factor in the 
pathophysiology of AION. This concept has been demon-
strated by monitoring the ambulatory blood pressure over 
the course of 24 hours, which has shown that nocturnal 
hypotension may act as the final insult that leads to isch-
emia and AION in optic nerves that have been previously 
rendered vulnerable to ischemia by predisposing factors. 
Beck et al. [7] have also noted that some discs have 
certain anatomic features that seem to predispose them 
to AION. Burde [8] has coined the term “disc at risk” to 
describe these structurally crowded discs, which are char-
acterized by a small nerve head with a small or absent 
physiologic cup, abnormal branching of the central vessels, 
and full nerve fiber bundles that obscure the disc margin. 
During sexual stimulation, the cavernous nerves release 
nitric oxide, which induces cyclic guanosine monophos-
phate (cGMP) formation and leads to smooth muscle relax-
ation and increased blood flow to the corpus cavernosum. 
This results in an erection. PDE5 is a naturally occurring 
enzyme that is found in high concentrations in the corporis 
cavernosum and that breaks down cGMP. Sildenafil citrate 
selectively inhibits PDE5, thus blocking the breakdown of 
cGMP and facilitating the erectile process [9]. 
It is hypothesized that the mild hypotensive effect of 
PDE5 inhibitors accentuate physiological nocturnal hypo-
tension, which may result in ischemia of the optic nerve 
head and compartment syndrome in a susceptible disc [10]. 
An alternative explanation is that these medications reduce 
optic nerve head perfusion or disrupt the ability to auto-
regulate due to the potentiation of nitric oxide [10]. 
There have been several case reports that have described 
AION in users of PDE5 inhibitors. Egan and Pomeranz 
[11] have reported on sildenafil-associated AION, and 
Cunningham and Smith [12] have also reported a case of 
anterior ischemic optic neuropathy associated with silde-
nafil (Viagra; Pfizer, New York, NY, USA). Bollinger and 
Lee [13] have reported a recurrent visual field defect and 
ischemic optic neuropathy associated with tadalafil rechal-
lenge. There have been no published case reports that have 
linked an episode of AION to udenafil.
The commonly associated systemic diseases include 
arterial hypertension, diabetes mellitus, ischemic heart 
disease, hyperlipidemia, cerebrovascular accidents, and 
arteriosclerosis [14]. Various associated systemic diseases 
may interfere with the autoregulation of blood flow in the 
optic nerve head and make the optic nerve head vulnerable 
to AION. Lee et al. [15] have reported that hypertension, 
high cholesterol and decreased cup-to-disc ratio were ob-
served in more than 60% of Korean patients with AION 
and thereby defined these as major risk factors.
Chung et al. [16] have reported that, of the 137 patients 
identified with AION in their study, the 28 smokers were 
statistically younger, with a mean age of 51 years, than the 
83 nonsmokers, who had a mean age of 64 years. They 
concluded that cigarette smoking is an important risk fac-
tor in the development of AION, and that the cessation of 
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Fig. 4. Ocular coherence tomography shows prominent thick-
ening of the retinal nerve fiber layer of the right eye. TEMP 
= temporal; SUP = superior; NAS = nasal; INF = inferior; 
OD = right eye; OS = left eye.
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smoking appears to reduce the risk of AION to that of the 
nonsmoking population. Lee et al. [15] have also reported 
that, of the 48 patients with AION in their study, the mean 
age of the nine smokers, was less than the 50.5 years of the 
nonsmokers. Of the nine smokers, four had smoking histo-
ry as the only risk factor for AION. The authors also sug-
gested that smoking is an important risk factor of AION 
and may be the only risk factor in younger patients. 
The differential diagnosis of AION included functional 
visual loss, retinopathy (hypertensive retinopathy, central 
serous retinopathy, congenital maculopathy, pigmentary 
reitnaopathy, amelanotic melanoma, and cellophane macu-
lopathy), amblyopia, glaucoma, keratoconus, pseudopap-
illedema, miscorrected refractive error, Leber’s congenital 
amaurosis, and cortical visual loss [16]. 
Although the funduscopic image and fundus fluorescein 
angiography were most consistent with AION, the possibil-
ity of inflammatory optic neuropathy (optic neuritis) was 
also considered. Laboratory testing revealed no evidence 
of systemic inflammation. The neurologic examination 
was also normal, and the MRI scan of the brain with gado-
linium enhancement demonstrated that the optic nerves 
appeared normal, and the lack of white matter lesions were 
not suggestive of demyelinating disease.
The actual duration of the pharmacologic effect of ude-
nafil is approximately 24 hours. Patients are told to take 
udenafil approximately 90 to 120 minutes prior to sexual 
intercourse. Since the patient in this case study took the 
udenafil at night and then fell asleep after sexual inter-
course, he noticed the visual field defect the following 
morning. We believe that udenafil may have contributed 
to the episode of AION in this patient. The risk factors of 
this patient were a decreased cup-to-disc ratio and a smok-
ing history. The udenafil may have sufficiently accentu-
ated his physiologic nocturnal hypotension to decrease the 
perfusion pressure in the posterior ciliary arteries. This 
may have resulted in ischemia of the disc that was already 
predisposed to AION due to the anatomic disc-at-risk 
configuration. The temporal relationship between the dose 
of udenafil and the onset of visual field defect make it dif-
ficult to accept the notion that these were unrelated coinci-
dental events.   
During the evaluation of patients with signs and symp-
toms of AION, a complete review of medications, includ-
ing questions about udenafil use, is essential. Patients 
may be reluctant to inform their doctors about their use 
of udenafil as a result of the stigma that is associated with 
erectile dysfunction.
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